Johannes A. Eble
Institute of Physiological Chemistry and Pathobiochemistry
University of Münster
Waldeyerstrasse 15
48149
Germany
Name/email consistency: high
- Integrins in cancer treatment. Eble, J.A., Haier, J. Curr. Cancer. Drug. Targets (2006)
- Collagen XVI harbors an integrin alpha1 beta1 recognition site in its C-terminal domains. Eble, J.A., Kassner, A., Niland, S., Mörgelin, M., Grifka, J., Grässel, S. J. Biol. Chem. (2006)
- Collagen-binding integrins as pharmaceutical targets. Eble, J.A. Curr. Pharm. Des. (2005)
- Vipera lebetina venom contains two disintegrins inhibiting laminin-binding beta1 integrins. Eble, J.A., Bruckner, P., Mayer, U. J. Biol. Chem. (2003)
- The alpha2beta1 integrin inhibitor rhodocetin binds to the A-domain of the integrin alpha2 subunit proximal to the collagen-binding site. Eble, J.A., Tuckwell, D.S. Biochem. J. (2003)
- Rhodocetin antagonizes stromal tumor invasion in vitro and other alpha2beta1 integrin-mediated cell functions. Eble, J.A., Niland, S., Dennes, A., Schmidt-Hederich, A., Bruckner, P., Brunner, G. Matrix Biol. (2002)
- alpha 2beta 1 integrin is not recognized by rhodocytin but is the specific, high affinity target of rhodocetin, an RGD-independent disintegrin and potent inhibitor of cell adhesion to collagen. Eble, J.A., Beermann, B., Hinz, H.J., Schmidt-Hederich, A. J. Biol. Chem. (2001)
- The molecular basis of integrin-extracellular matrix interactions. Eble, J.A. Osteoarthr. Cartil. (2001)
- Recombinant soluble human alpha 3 beta 1 integrin: purification, processing, regulation, and specific binding to laminin-5 and invasin in a mutually exclusive manner. Eble, J.A., Wucherpfennig, K.W., Gauthier, L., Dersch, P., Krukonis, E., Isberg, R.R., Hemler, M.E. Biochemistry (1998)









